Savara Inc
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2020 Ended Jun 30, 2020 | Aug 6, 2020 | During market hours | – | – | – |
| Q1 FY2020 Ended Mar 31, 2020 | May 7, 2020 | During market hours | – | – | – |
| Q4 FY2019 Ended Dec 31, 2019 | Mar 12, 2020 | During market hours | – | – | – |
| Q3 FY2019 Ended Sep 30, 2019 | Nov 7, 2019 | During market hours | – | – | – |
| Q2 FY2019 Ended Jun 30, 2019 | Aug 8, 2019 | During market hours | – | – | – |
| Q1 FY2019 Ended Mar 31, 2019 | May 9, 2019 | During market hours | – | – | – |
| Q4 FY2018 Ended Dec 31, 2018 | Mar 13, 2019 | During market hours | – | – | – |
| Q3 FY2018 Ended Sep 30, 2018 | Nov 7, 2018 | During market hours | – | – | – |
| Q2 FY2018 Ended Jun 30, 2018 | Aug 9, 2018 | During market hours | – | – | – |
| Q1 FY2018 Ended Mar 31, 2018 | May 9, 2018 | During market hours | – | – | – |
| Q4 FY2017 Ended Dec 31, 2017 | Mar 14, 2018 | During market hours | – | – | – |
| Q3 FY2017 Ended Sep 30, 2017 | Nov 8, 2017 | During market hours | – | – | – |
Press releases
Announcements Savara filed with the SEC
Developing new therapies for rare respiratory diseases Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
SAVARA ANNOUNCES PRICING OF $130.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS
Material agreement · Other events · EX-99.1 to Form 8-K
SAVARA ANNOUNCES $75M ROYALTY FUNDING AGREEMENT WITH RTW TO
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corporate Overview October 2025 ©
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Therapies for Rare Respiratory Diseases September 2025 © Savara Inc. All Rights Reserved. Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
SAVARA RECEIVES REFUSAL TO FILE (RTF) LETTER FROM THE U.S. FOOD AND
Other events · EX-99.1 to Form 8-K
SAVARA ENTERS INTO NON-DILUTIVE DEBT FINANCING FOR UP TO $200M
Material agreement · Agreement terminated · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Respiratory Diseases January 2025 © Savara Inc. All Rights Reserved.
Regulation FD disclosure · EX-99.1 to Form 8-K
SAVARA ANNOUNCES PRICING OF $100.0 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK
Material agreement · Other events · EX-99.1 to Form 8-K
SAVARA ANNOUNCES MOLGRAMOSTIM NEBULIZER SOLUTION (MOLGRAMOSTIM) ACHIEVED STATISTICAL SIGNIFICANCE FOR
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SAVARA ANNOUNCES PRICING OF $80 MILLION UNDERWRITTEN OFFERING OF COMMON
Material agreement · Other events · EX-99.1 to Form 8-K
Therapies for Rare Respiratory Diseases June 2023 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapies for Rare Respiratory Diseases January 2022 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K